| Company | Pipeline | Area | Indication | Development Process | Remarks |
|---|---|---|---|---|---|
|
|||||
|
Lurasidone | CNS |
Schizophrenia and bipolar disorder |
|
Launched August 1, 2024 |
|
Major Depressive Disorder |
|
Phase 3 IND Submission |
|||
| BUK-001 | CNS |
Parkinson’s disease |
|
Lead Candidate Expected (1H 2026) |
|
|
CP-012 | CNS |
Morning OFF in Parkinson’s disease |
|
Phase 2 Preparation |
| CP-102 | Rare |
Canavan disease |
|
Preclinical | |
| CP-10X | Kidney |
Chronic kidney disease |
|
Discovery | |
| Others | Rare |
Rare diseases |
|
Preclinical | |
|
AHR Antagonist |
Cancer |
AhR-mediated disorders |
|
Development path under strategic review |